Avid Bioservices Inc (CDMO)

[Bungler]

Certainly makes sense from the perspective of best practices in a double-blinded study to prevent an entity from having even the ability to mix-up coding and labeling of the investigational new drug and the placebo. If they never get their hands on placebo in the first place, there is no chance of such error, none, zero. Why, what reason would there be for this precautionary procedure NOT to be taken? Cost? Pennywise and pound foolish?

Appreciate your reply. You still have not addressed the substance of my prior response.